Bristol Myers Squibb’s Positive Zenbexus Data Put Multiple Myeloma Pipeline in Focus
Bristol Myers Squibb reported positive Phase 3 Zenbexus data, putting its multiple myeloma pipeline and potential regulatory path under investor scrutiny.
FDA Expands Tecentriq Use to Stage III Colon Cancer in Roche Oncology Boost
FDA approval of Tecentriq in stage III colon cancer expands Roche’s oncology opportunity and adds a …
Teva Shares Rise as FDA Approves Once-Monthly Weltruza Schizophrenia Treatment
Teva shares rose 3.5% to 4.5% premarket after FDA approval of once-monthly Weltruza, sharpening focu…
Crescent Energy’s $4.2 Billion Eagle Ford Deal Tests Balance Sheets and US Shale Consolidation
Crescent Energy’s Eagle Ford acquisition expands CRGY’s shale footprint while forcing investors to w…
Lipocine’s 30% Surge After Canadian TLANDO Approval Puts Regulatory Catalysts in Focus
Lipocine’s LPCN shares rose 30% after Health Canada approved TLANDO, expanding the drug’s cross-bord…
Viatris-Pacira $36.50 Cash Deal Puts Merger-Arbitrage Focus on VTRS and PCRX
Viatris’s $36.50-per-share cash agreement to acquire Pacira puts PCRX’s deal spread and VTRS’s balan…
Lipocine Shares Jump 30% After Health Canada Approves TLANDO Testosterone Therapy
Lipocine shares surged 30% after Health Canada approved TLANDO, expanding the oral testosterone ther…
ArriVent BioPharma Plunges 47% After Phase III Lung Cancer Trial Miss
ArriVent’s $AVBP stock fell 46.98% after its FURVENT Phase III trial missed its primary endpoint, cu…
Viatris’ $36.50-a-Share Pacira Deal Signals Fresh Consolidation in Specialty Pharma
Viatris’ all-cash Pacira acquisition highlights continued US pharmaceutical consolidation and puts s…
SeaStar Medical’s FDA Breakthrough Designation Puts $ICU on the Investor Watchlist
SeaStar Medical’s FDA Breakthrough Device designation for its sepsis-therapy device could sharpen in…